#1 Clinical Trials Search in Europe

Study on the Effectiveness of Povidone-Iodine for Nasal Decolonization in Patients with MRSA

2 1 1 1

What is this study about?

This clinical trial is focused on studying the effectiveness of a treatment for patients with (Methicillin-resistant Staphylococcus aureus), a type of bacterial infection that is resistant to many antibiotics. The treatment being tested is a nasal gel containing , a substance known for its ability to kill bacteria. The purpose of the study is to evaluate how well this nasal gel can remove MRSA from the nose of patients.

Participants in the study will use a nasal gel as part of a complete decolonization kit. The study will observe the rate at which MRSA is cleared from the nose six hours after applying the gel. The study will also assess how acceptable the treatment is to patients and healthcare workers through a questionnaire. Additionally, the study will monitor any side effects reported by patients and check the MRSA status again 24 hours after using the kit.

The trial aims to provide valuable information on the effectiveness of the nasal gel in reducing MRSA in patients. This could potentially lead to better treatment options for those affected by this resistant bacterial infection. The study will be conducted over a period, with results expected to help understand the characteristics of patients who remain MRSA positive after using the gel.

1 joining the study

Upon joining the study, ensure that all eligibility criteria are met. This includes being over 18 years old, having a hospital stay longer than 4 days, and being informed about the study. Written consent is required.

2 initial screening

Undergo a nasal screening to confirm MRSA positivity. This is a necessary step to participate in the trial.

3 application of nasal gel

Apply the povidone iodine gel to the nasal area. This is a topical treatment aimed at reducing MRSA presence. Follow the instructions provided for correct application.

4 waiting period

Wait for 6 hours after the application of the nasal gel. This period is crucial for assessing the effectiveness of the treatment.

5 first follow-up screening

Undergo a nasal screening 6 hours after the application to evaluate the decolonization rate of MRSA.

6 self-questionnaire

Complete a self-questionnaire to provide feedback on the acceptability of the nasal decolonization kit. This helps in understanding the user experience.

7 second follow-up screening

Undergo another nasal screening 24 hours after the initial application to further assess the decolonization rate.

8 reporting adverse events

Report any adverse events experienced during the trial. This information is important for evaluating the safety of the treatment.

Who Can Join the Study?

  • Patients who have been readmitted to the hospital and are already positive for MRSA (a type of bacteria that is resistant to many antibiotics) through a nasal screening test.
  • Patients who have been in the hospital for more than 4 days.
  • Patients who are older than 18 years.
  • Patients who have been informed about the study and understand it.
  • Patients who agree to participate and provide their written consent.
  • Patients who are part of the French social security system or are beneficiaries of it.

Who Cannot Join the Study?

  • Patients who are not diagnosed with MRSA (Methicillin-resistant Staphylococcus aureus) cannot participate.
  • Patients who are younger than 3 years old or older than 4 years old cannot participate.
  • Patients who are not part of the specified clinical trial group cannot participate.
  • Patients who are not considered part of a vulnerable population cannot participate.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

No sites found in this category

Other Sites

Site Name City Country Status
Centre Hospitalier Universitaire De Nantes Nantes France

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
France France
Not recruiting
02.01.2023

Trial locations

Investigated drugs:

Povidone Iodine is a type of antiseptic that is used to kill bacteria and other germs. In this clinical trial, it is applied as a gel inside the nose to help remove a specific type of bacteria called MRSA. MRSA can cause infections, and the goal of using this gel is to reduce or eliminate the bacteria from the nasal area. The trial aims to see how effective this treatment is in getting rid of MRSA within a few hours after application.

Methicillin-resistant Staphylococcus aureus (MRSA) infection – This infection is caused by a type of staph bacteria that has become resistant to many antibiotics used to treat ordinary staph infections. MRSA can cause a variety of problems ranging from skin infections to more severe infections such as pneumonia or bloodstream infections. It often begins as a small red bump that resembles a pimple, boil, or spider bite. These can quickly turn into deep, painful abscesses that require surgical draining. Sometimes the bacteria remain confined to the skin, but they can also burrow deeper into the body, causing potentially more serious infections. The bacteria are typically spread by direct contact with an infected wound or by sharing personal items that have touched infected skin.

Trial ID:
2022-500642-25-00
Protocol code:
RC21_0556
Trial Phase:
Therapeutic exploratory (Phase II)

Other Trials to Consider

  • A study evaluating the effectiveness of cineole compared to mupirocin in patients with chronic Staphylococcus aureus infection or carriage in the nasal cavity.

    Not yet recruiting

    3 1 1 1
    Poland

  • Title: “Study comparing standard decolonization therapy alone versus combined with oral clindamycin for patients with MRSA throat carriage”

    Not recruiting

    3 1 1 1
    Investigated drugs:
    Denmark